drugset / Trial / NCT00019747
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Phase 2
Terminated
39 enrolled
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying surgery and thalidomide to see how well they work compared to surgery alone in treating patients with recurrent or metastatic colorectal cancer.
Timeline
- Start
- 1999-08
- Primary completion
- 2008-12
- Completion
- 2008-12
Outcome
Outcome not reported
Stopped (Enrollment): “DSMB recommended closure of the protocol due to slow accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 300 mg | Oral |